title: Tumor-antigen-binding bispecific antibodies for cancer treatment.
abstract: Bi- and multispecific antibody derivatives (bsAbs) can be considered as the next generation of targeted biologics for cancer therapy. The general concept of bsAbs is a physical connection of recombinant antibody-derived entities with at least two binding specificities. This generates bsAbs that bind at least two antigens or epitopes, thus altering their binding functionalities and specificities in comparison to "normal" antibodies. Most bsAbs are produced as recombinant proteins, either as large IgG-like proteins that contain Fc regions, or as smaller entities with multiple antigen-binding regions but without Fc. Application of bsAbs in experimental cancer therapy currently includes molecules that bind different cell surface proteins to achieve more complete blockage of proliferative or angiogenesis-associated pathways. This approach of blocking more than one pathway component, or to simultaneously hit complementing pathways, also may limit potential escape mechanisms of cancer cells. BsAbs also are applied in the clinic as vehicles to deliver immune effector cells and/or cytokines to tumors.
authors.affiliation: Roche Pharmaceuticals Research and Early Development (pRED), Discovery Oncology (UHW) and Large Molecule Research (UB), Roche Innovation Center Penzberg, Germany.
authors.forename: Ulrich H
authors.initials: UH
authors.lastname: Weidle
authors.affiliation: Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany.
authors.forename: Roland E
authors.initials: RE
authors.lastname: Kontermann
authors.affiliation: Roche Pharmaceuticals Research and Early Development (pRED), Discovery Oncology (UHW) and Large Molecule Research (UB), Roche Innovation Center Penzberg, Germany. Electronic address: ulrich.brinkmann@roche.com.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Brinkmann
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000276:immunology / Q000378:metabolism / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000378:metabolism / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology* / Q000378:metabolism*; D001666:Binding Sites, Antibody; D006801:Humans; D009369:Neoplasms / Q000276:immunology / Q000378:metabolism / Q000628:therapy*
chemical_list: D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm